

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACTAVIS LLC,
Petitioner

v.

ABRAXIS BIOSCIENCE, LLC,
Patent Owner

Case IPR2017-01100
Patent 8,853,260 B2

**DECLARATION OF EDMUND J. ELDER, Jr., Ph.D., R.Ph.
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW**

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. BACKGROUND AND QUALIFICATIONS	2
III. LEGAL STANDARDS USED IN MY ANALYSIS	6
A. Prior art	6
B. Person of ordinary skill in the art	7
C. Obviousness	8
IV. OBVIOUSNESS	11
A. Increasing the concentration of active drug in pharmaceutical formulations was generally obvious and routine as of June 1997.	13
B. Reducing the particle size of pharmaceutical formulations was generally obvious and routine as of June 1997.	15
C. Optimizing the physical stability of pharmaceutical suspensions was generally obvious and routine as of June 1997.	17
D. The allegedly “unexpected” results asserted by Patent Owner regarding stability would have been expected as of June 1997.	20
V. CONCLUSION	22

EXHIBITS CITED

EX	Description
1001	Desai et al., U.S. Patent No. 8,853,260 B2, “Formulations of Pharmacological Agents, Methods for the Preparation thereof and Methods for the Use thereof” (issued Oct. 7, 2014) (the “’260 patent”)
1002	Declaration of Cory J. Berkland, Ph.D. in Support of Petition for <i>Inter Partes</i> Review
1003	Desai et al., U.S. Patent No. 5,439,686, “Methods for <i>In Vivo</i> Delivery of Substantially Water Insoluble Pharmacologically Active Agents and Compositions Useful therefor” (issued Aug. 8, 1995) (“Desai”)
1004	Shively, U.S. Patent No. 5,407,683, “Pharmaceutical Solutions and Emulsions Containing Taxol” (issued Apr. 18, 1995) (“Shively”)
1005	Liversidge et al., U.S. Patent No. 5,399,363, “Surface Modified Anticancer Nanoparticles” (issued Mar. 21, 1995) (“Liversidge”)
1006	<i>Remington’s Pharmaceutical Sciences</i> (18th ed. 1990), Chapt. 19, “Disperse Systems,” and Chapt. 78, “Sterilization” (“ <i>Remington’s</i> ”)
1024	U.S. Application No. 11/520,479, Supplemental Declaration of Neil P. Desai Pursuant to 37 C.F.R. § 1.132 (dated Nov. 1, 2013) (“Second Inventor Declaration”)
1027	List et al., U.S. Patent No. 5,389,382, “Hydrosols of Pharmacologically Active Agents and their Pharmaceutical Compositions Comprising Them” (issued Feb. 14, 1995) (“List”)

I, Edmund J. Elder, Jr., Ph.D., R.Ph., hereby declare as follows:

I. INTRODUCTION

1. I am the Director of the Zeeh Pharmaceutical Experiment Station at the School of Pharmacy at the University of Wisconsin-Madison. I have been retained by Petitioner Actavis LLC in connection with its request for *inter partes* review of U.S. Patent No. 8,853,260 (“the ’260 patent”). A copy of the ’260 patent has been marked EX1001. I have reviewed and am familiar with the ’260 patent. Generally, it describes and claims pharmaceutical compositions comprising the anticancer drug paclitaxel bound to the protein albumin and formulated as nanoparticles, and methods of using such compositions to treat diseases including cancer.

2. I have been asked to provide my independent opinions regarding the patentability of claims 1–27 of the ’260 patent (the “challenged claims”) and to review the Declaration of Cory J. Berkland in Support of Petition for *Inter Partes* Review, which has been marked EX1002. This declaration includes a discussion of my background and qualifications, the legal standards used in my analysis, and my opinions and relevant experiences as a person of ordinary skill in the art as of June 1997 (a “skilled artisan”) regarding the subject matter of the ’260 patent.

3. I am being compensated for my work in this proceeding at my standard hourly consulting rate of \$500.00 per hour. My compensation is in no way contingent on the substance of my opinions or the outcome of this proceeding.

4. As set forth more fully below, it is my opinion that the challenged claims are unpatentable because they would have been obvious to a skilled artisan as of June 1997 in view of U.S. Patent No. 5,439,686 to Desai et al. (“Desai”) (EX1003), U.S. Patent No. 5,407,683 to Shively (“Shively”) (EX1004), U.S. Patent No. 5,399,363 to Liversidge et al. (“Liversidge”) (EX1005), and *Remington’s Pharmaceutical Sciences* (18th ed. 1990) (“*Remington’s*”) (EX1006). The bases for my opinions are set forth in this declaration.

II. BACKGROUND AND QUALIFICATIONS

5. I obtained my Bachelor of Science degree in Pharmacy, and my Doctor of Philosophy (Ph.D.) degree in Pharmaceutical Sciences, from the Medical University of South Carolina in 1985 and 1989, respectively. I have over 30 years of experience characterizing materials used in the preparation of pharmaceutical products, formulating pharmaceutical products, and testing such formulations.

6. My current responsibilities as Director of the Zeeh Pharmaceutical Experiment Station at the University of Wisconsin-Madison (“the Station”) include overseeing all aspects of our services, including providing pharmaceutical pre-formulation and formulation expertise to support pharmaceutical and biopharmaceutical development collaborations across the University of Wisconsin system campuses and for clients outside the University. The Station works for both academia and pharmaceutical industry clients in developing and characterizing drugs and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.